Peptides May Soon Be Legal. These Companies Are Ready To Cash In

Key Points:

• An FDA panel is meeting to consider recommending legal production of seven peptides currently restricted to research use, attracting major compounding pharmacies, telehealth companies, and longevity influencers eager to enter a potentially multi-billion-dollar market.
• These peptides, such as BPC-157 and TB-500, are popular in the gray market despite lacking robust scientific evidence on safety and efficacy, raising concerns among public health experts about unregulated use and potential risks.
• Proponents argue legalization would improve safety by moving users away from unregulated sources, but the FDA's technical staff and some health groups warn that approval could legitimize unproven treatments and lead to widespread availability of "snake oil."
• Compounding pharmacies like Empower Pharmacy and Strive Pharmacy are preparing to manufacture these peptides pending FDA approval, seeing them as a lucrative new product line after the GLP-1 weight-loss drug market stabilized.
• Challenges remain in establishing compliant ingredient supply chains and regulatory frameworks, but industry insiders expect the peptide market to rival or exceed the recent GLP-1 drug boom in size and impact.